Dear Shareholders, In 2015, Celyad set solid foundations to support its growth in 2016 and beyond. Thanks to its latest technological acquisition and its introduction on Nasdaq, Celyad moved from a Belgian cell therapy company specialized in ischemic heart failure to a global player which has the means and competency to develop clinical programs both in cardiovascular disease and in immuno-oncology, across Europe, U.S. and Asia.
Footer
Celyad Oncology
